Inhibrx Biosciences (INBX) stock is reacting to fresh financing news after the company expanded its credit facility to up to $500 million through a Second Amendment with Oxford Finance.

For context, Inhibrx Biosciences shares trade at US$79.68 after the financing announcement, with the stock down over the past month and quarter, yet still showing a positive year to date share price return and a very large 1 year total shareholder return of 246.59%. This may indicate that prior optimism is now being reassessed as investors weigh the larger debt facility and associated risks.

If you are interested in what else could be moving on financing and growth stories in healthcare, this is a good moment to scan 40 healthcare AI stocks

Inhibrx Biosciences now trades far below the average analyst price target, even after the stock’s sharp pullback on the larger credit facility. Is this a reasonable safety discount, or is the market being overly cautious on the debt load?

Preferred multiple of price to book: Is it justified?

On the latest data, Inhibrx Biosciences carries a P/B ratio of 55.6x based on its negative equity position, compared with an average P/B of 2.4x for the broader US biotech sector. That gap is wide, and it sits alongside a peer average of 4.8x. This highlights how far the company’s balance sheet profile differs from both the industry and closer comparables.

P/B looks at the share price relative to the book value of equity on the balance sheet. For many profitable companies this can help you gauge how much investors are paying for each dollar of net assets. Inhibrx Biosciences is currently loss making, has negative shareholders’ equity and relies on higher risk external borrowing according to Simply Wall St’s checks, so this metric is sending a very different signal.

Compared with both the US Biotechs industry P/B of 2.4x and the peer average of 4.8x, the current 55.6x level stands out as extremely high. It reflects a balance sheet where liabilities exceed assets rather than a premium on strong equity value, and helps explain why traditional valuation yardsticks can be difficult to interpret for this stock right now.

Result: Price-to-book of 55.6x (ABOUT RIGHT as a reflection of negative equity, not a conventional valuation signal).

However, the enlarged credit facility and ongoing net loss of US$130.185 million keep financing and balance sheet risk firmly in focus for Inhibrx Biosciences investors.

Next Steps

With sentiment on Inhibrx Biosciences looking mixed, with clear risks and some potential rewards, it makes sense to review the data and move quickly to form your own view using the 1 key reward and 3 important warning signs

Looking for more investment ideas beyond Inhibrx Biosciences?

If Inhibrx Biosciences has you rethinking risk and reward, now is a great time to broaden your watchlist with fresh ideas from other parts of the market.

• Target dependable income by reviewing companies in the 8 dividend fortresses that may suit a yield focused approach.
• Spot potential value opportunities by scanning the 49 high quality undervalued stocks and comparing how their fundamentals stack up.
• Prioritise resilience by checking companies in the 83 resilient stocks with low risk scores that score well on financial strength and risk metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.